Qiagen NV Share Price Nasdaq
Stocks
NL0000240000
Biotechnology & Medical Research
| Market Cap | 9.2B 7.89B 7.37B 6.76B 12.72B 880B 12.93B 86.98B 34.06B 441B 34.55B 33.8B 1,459B | P/E 2026 * |
21.3x | P/E 2027 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.79B 8.4B 7.84B 7.19B 13.53B 936B 13.75B 92.52B 36.23B 469B 36.76B 35.96B 1,552B | EV / Sales 2026 * |
4.57x | EV / Sales 2027 * | 4.18x |
| Free-Float |
99.37% | Yield 2026 * |
0.58% | Yield 2027 * | 0.72% |
Last Transcript: Qiagen NV
| 1 day | -2.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 61 | 06/10/2019 |
Roland Sackers
DFI | Director of Finance/CFO | 58 | 31/12/2003 |
Antonio Santos
COO | Chief Operating Officer | - | 31/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 31/05/2011 | |
Toralf Haag
BRD | Director/Board Member | 60 | 07/01/2021 |
Eva Pisa
BRD | Director/Board Member | 72 | 22/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.28% | -4.05% | - | - | 9.2B | |
| +2.37% | +2.30% | +3.39% | +22.74% | 50.5B | |
| -0.62% | +4.58% | +487.47% | +624.71% | 46.01B | |
| +2.09% | +4.96% | +20.59% | +95.21% | 42.85B | |
| +3.85% | +3.13% | +29.60% | +16.50% | 41.03B | |
| -0.72% | -3.91% | +17.87% | +47.98% | 32.02B | |
| +3.04% | +1.89% | +31.62% | +143.62% | 16.98B | |
| +4.33% | +1.63% | - | - | 17.05B | |
| +1.44% | +1.52% | +4.22% | +31.00% | 14.3B | |
| +3.87% | +1.98% | +82.99% | +45.80% | 13.84B | |
| Average | +1.74% | +2.01% | +84.72% | +128.44% | 30.51B | |
| Weighted average by Cap. | +1.74% | +2.37% | +104.90% | +154.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.14B 1.84B 1.72B 1.57B 2.96B 205B 3.01B 20.26B 7.93B 103B 8.05B 7.87B 340B | 2.25B 1.93B 1.8B 1.65B 3.11B 215B 3.16B 21.28B 8.33B 108B 8.46B 8.27B 357B |
| Net income | 399M 342M 319M 293M 551M 38.12B 560M 3.77B 1.48B 19.12B 1.5B 1.47B 63.22B | 479M 411M 384M 352M 662M 45.77B 673M 4.53B 1.77B 22.95B 1.8B 1.76B 75.89B |
| Net Debt | 587M 503M 470M 431M 811M 56.08B 824M 5.55B 2.17B 28.13B 2.2B 2.16B 93B | 214M 184M 171M 157M 296M 20.46B 301M 2.02B 792M 10.26B 804M 786M 33.92B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
